EGFR and non-small cell lung carcinoma: To determine whether the accumulation of ACh also occurs in EGFR-TKI–regressed tumors, we investigated the changes in ACh metabolism in osimertinib-regressed patient-derived xenograft (PDX) tumors (37) established from EGFR-mutant NSCLC patients.